nach oben

European Journal of Nuclear Medicine and Molecular Imaging

Erschienen in:

19.12.2015 | Original Article

Imaging with ¹²⁴I in differentiated thyroid carcinoma: is PET/MRI superior to PET/CT?

verfasst von: I. Binse, T. D. Poeppel, M. Ruhlmann, B. Gomez, L. Umutlu, A. Bockisch, S. J. Rosenbaum-Krumme

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 6/2016

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The aim of this study was to compare integrated PET/CT and PET/MRI for their usefulness in detecting and categorizing cervical iodine-positive lesions in patients with differentiated thyroid cancer using ¹²⁴I as tracer.

Methods

The study group comprised 65 patients at high risk of iodine-positive metastasis who underwent PET/CT (low-dose CT scan, PET acquisition time 2 min; PET/CT₂) followed by PET/MRI of the neck 24 h after ¹²⁴I administration. PET images from both modalities were analysed for the numbers of tracer-positive lesions. Two different acquisition times were used for the comparisons, one matching the PET/CT₂ acquisition time (2 min, PET/MRI₂) and the other covering the whole MRI scan time (30 min, PET/MRI₃₀). Iodine-positive lesions were categorized as metastasis, thyroid remnant or inconclusive according to their location on the PET/CT images. Morphological information provided by MRI was considered for evaluation of lesions on PET/MRI and for volume information.

Results

PET/MRI₂ detected significantly more iodine-positive metastases and thyroid remnants than PET/CT₂ (72 vs. 60, p = 0.002, and 100 vs. 80, p = 0.001, respectively), but the numbers of patients with at least one tumour lesion identified were not significantly different (21/65 vs. 17/65 patients). PET/MRI₃₀ tended to detect more PET-positive metastases than PET/MRI₂ (88 vs. 72), but the difference was not significant (p = 0.07). Of 21 lesions classified as inconclusive on PET/CT, 5 were assigned to metastasis or thyroid remnant when evaluated by PET/MRI. Volume information was available in 34 % of iodine-positive metastases and 2 % of thyroid remnants on PET/MRI.

Conclusions

PET/MRI of the neck was found to be superior to PET/CT in detecting iodine-positive lesions. This was attributed to the higher sensitivity of the PET component, Although helpful in some cases, we found no substantial advantage of PET/MRI over PET/CT in categorizing iodine-positive lesions as either metastasis or thyroid remnant. Volume information provided by MRI for some iodine-positive lesions might be useful in dosimetry.

Freudenberg LS, Jentzen W, Stahl A, Bockisch A, Rosenbaum-Krumme SJ. Clinical applications of 124I-PET/CT in patients with differentiated thyroid cancer. Eur J Nucl Med Mol Imaging. 2011;38 Suppl 1:S48–56. doi:10.1007/s00259-011-1773-5.CrossRefPubMed

Jentzen W, Freudenberg L, Eising EG, Sonnenschein W, Knust J, Bockisch A. Optimized 124I PET dosimetry protocol for radioiodine therapy of differentiated thyroid cancer. J Nucl Med. 2008;49:1017–23. doi:10.2967/jnumed.107.047159.CrossRefPubMed

Jentzen W, Hoppenbrouwers J, van Leeuwen P, van der Velden D, van de Kolk R, Poeppel TD, et al. Assessment of lesion response in the initial radioiodine treatment of differentiated thyroid cancer using 124I PET imaging. J Nucl Med. 2014;55:1759–65. doi:10.2967/jnumed.114.144089.CrossRefPubMed

Lee J, Nah KY, Kim RM, Oh YJ, An YS, Yoon JK, et al. Effectiveness of [(124)I]-PET/CT and [(18)F]-FDG-PET/CT for localizing recurrence in patients with differentiated thyroid carcinoma. J Korean Med Sci. 2012;27:1019–26. doi:10.3346/jkms.2012.27.9.1019.CrossRefPubMedPubMedCentral

de Pont C, Halders S, Bucerius J, Mottaghy F, Brans B. 124I PET/CT in the pretherapeutic staging of differentiated thyroid carcinoma: comparison with posttherapy 131I SPECT/CT. Eur J Nucl Med Mol Imaging. 2013;40:693–700. doi:10.1007/s00259-012-2331-5.CrossRefPubMed

Van Nostrand D, Moreau S, Bandaru VV, Atkins F, Chennupati S, Mete M, et al. (124)I positron emission tomography versus (131)I planar imaging in the identification of residual thyroid tissue and/or metastasis in patients who have well-differentiated thyroid cancer. Thyroid. 2010;20:879–83. doi:10.1089/thy.2009.0430.CrossRefPubMed

Czernin J, Herrmann K. The potential of PET/MRI imaging in oncology: a comment to a summary report of the First PET/MRI Workshop in Tuebingen in 2012. Mol Imaging Biol. 2013;15:372–3. doi:10.1007/s11307-013-0642-y.CrossRefPubMedPubMedCentral

Delso G, Furst S, Jakoby B, Ladebeck R, Ganter C, Nekolla SG, et al. Performance measurements of the Siemens mMR integrated whole-body PET/MR scanner. J Nucl Med. 2011;52:1914–22. doi:10.2967/jnumed.111.092726.CrossRefPubMed

Czernin J, Ta L, Herrmann K. Does PET/MR imaging improve cancer assessments? Literature evidence from more than 900 patients. J Nucl Med. 2014;55:59S–62S. doi:10.2967/jnumed.114.141838.CrossRefPubMed

10.

Antoch G, Bockisch A. Combined PET/MRI: a new dimension in whole-body oncology imaging? Eur J Nucl Med Mol Imaging. 2009;36 Suppl 1:S113–20. doi:10.1007/s00259-008-0951-6.CrossRefPubMed

11.

Mattsson S, Soderberg M. Radiation dose management in CT, SPECT/CT and PET/CT techniques. Radiat Prot Dosim. 2011;147:13–21. doi:10.1093/rpd/ncr261.CrossRef

12.

Martinez-Moller A, Souvatzoglou M, Delso G, Bundschuh RA, Chefd’hotel C, Ziegler SI, et al. Tissue classification as a potential approach for attenuation correction in whole-body PET/MRI: evaluation with PET/CT data. J Nucl Med. 2009;50:520–6. doi:10.2967/jnumed.108.054726.CrossRefPubMed

13.

Wiesmuller M, Quick HH, Navalpakkam B, Lell MM, Uder M, Ritt P, et al. Comparison of lesion detection and quantitation of tracer uptake between PET from a simultaneously acquiring whole-body PET/MR hybrid scanner and PET from PET/CT. Eur J Nucl Med Mol Imaging. 2013;40:12–21. doi:10.1007/s00259-012-2249-y.CrossRefPubMed

14.

Finkelstein SE, Grigsby PW, Siegel BA, Dehdashti F, Moley JF, Hall BL. Combined [18F]fluorodeoxyglucose positron emission tomography and computed tomography (FDG-PET/CT) for detection of recurrent, 131I-negative thyroid cancer. Ann Surg Oncol. 2008;15:286–92. doi:10.1245/s10434-007-9611-5.CrossRefPubMed

15.

Loeffelbein DJ, Souvatzoglou M, Wankerl V, Martinez-Moller A, Dinges J, Schwaiger M, et al. PET-MRI fusion in head-and-neck oncology: current status and implications for hybrid PET/MRI. J Oral Maxillofac Surg. 2012;70:473–83. doi:10.1016/j.joms.2011.02.120.CrossRefPubMed

16.

Liu Z, Xun X, Wang Y, Mei L, He L, Zeng W, et al. MRI and ultrasonography detection of cervical lymph node metastases in differentiated thyroid carcinoma before reoperation. Am J Transl Res. 2014;6:147–54.PubMedPubMedCentral

17.

Chen Q, Raghavan P, Mukherjee S, Jameson MJ, Patrie J, Xin W, et al. Accuracy of MRI for the diagnosis of metastatic cervical lymphadenopathy in patients with thyroid cancer. Radiol Med. 2015;120(10):959–66. doi:10.1007/s11547-014-0474-0.CrossRefPubMed

18.

Kuhn FP, Hullner M, Mader CE, Kastrinidis N, Huber GF, von Schulthess GK, et al. Contrast-enhanced PET/MR imaging versus contrast-enhanced PET/CT in head and neck cancer: how much MR information is needed? J Nucl Med. 2014;55:551–8. doi:10.2967/jnumed.113.125443.CrossRefPubMed

19.

Queiroz MA, Hullner M, Kuhn F, Huber G, Meerwein C, Kollias S, et al. PET/MRI and PET/CT in follow-up of head and neck cancer patients. Eur J Nucl Med Mol Imaging. 2014;41:1066–75. doi:10.1007/s00259-014-2707-9.CrossRefPubMed

20.

Nagarajah J, Jentzen W, Hartung V, Rosenbaum-Krumme S, Mikat C, Heusner TA, et al. Diagnosis and dosimetry in differentiated thyroid carcinoma using 124I PET: comparison of PET/MRI vs PET/CT of the neck. Eur J Nucl Med Mol Imaging. 2011;38:1862–8. doi:10.1007/s00259-011-1866-1.CrossRefPubMed

21.

Seiboth L, Van Nostrand D, Wartofsky L, Ousman Y, Jonklaas J, Butler C, et al. Utility of PET/neck MRI digital fusion images in the management of recurrent or persistent thyroid cancer. Thyroid. 2008;18:103–11. doi:10.1089/thy.2007.0135.CrossRefPubMed

22.

Jentzen W, Freudenberg L, Bockisch A. Quantitative imaging of (124)I with PET/ CT in pretherapy lesion dosimetry. Effects impairing image quantification and their corrections. Q J Nucl Med Mol Imaging. 2011;55:21–43.PubMed

Titel: Imaging with 124I in differentiated thyroid carcinoma: is PET/MRI superior to PET/CT?
verfasst von: I. Binse
T. D. Poeppel
M. Ruhlmann
B. Gomez
L. Umutlu
A. Bockisch
S. J. Rosenbaum-Krumme
Publikationsdatum: 19.12.2015
Verlag: Springer Berlin Heidelberg
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 6/2016
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-015-3288-y

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2016

Peptide receptor radionuclide therapy with 177Lu-DOTATATE in advanced bronchial carcinoids: prognostic role of thyroid transcription factor 1 and 18F-FDG PET

Amyloid-independent functional neural correlates of episodic memory in amnestic mild cognitive impairment

Imaging of differentiated thyroid carcinoma: 124I-PET/MRI may not be superior to 124I-PET/CT

[123]FP-CIT SPECT scans initially rated as normal became abnormal over time in patients with probable dementia with Lewy bodies

Central serotonin transporter availability in highly obese individuals compared with non-obese controls: A [11C] DASB positron emission tomography study

Evaluation of 124I PET/CT and 124I PET/MRI in the management of patients with differentiated thyroid cancer